ESC

No companies found. Try a different search term.

How Stryker Makes its Money: Revenue Breakdown

A breakdown of Stryker (SYK) financials. See how Stryker makes money from MedSurg & Neurotechnology, Orthopaedics & Spine using their 2024 annual report.

Stryker at a Glance
Company
Stryker
Ticker
SYK
Sector
Medical Devices
Market Cap
$130B
Last Updated
March 18, 2026
Source
SEC Filings (10-K)

How Does Stryker Make its Money?

Stryker is one of the world’s leading medical technology companies, specializing in orthopaedic implants, surgical instruments, and neurotechnology. The company’s products range from hip and knee replacements to surgical navigation systems, endoscopy equipment, and hospital beds. Stryker is known for its Mako robotic-arm assisted surgery platform, which has become a key growth driver in orthopaedics. The company has a strong track record of acquisitive growth, completing numerous bolt-on acquisitions annually.

Stryker (SYK) Business Model

Stryker operates in the medical devices sector. Below is a summary of Stryker’s revenue streams, how the company generates income, and the key financial metrics from its most recent annual report. This breakdown uses data from Stryker’s 2024 fiscal year filings with the SEC.

Stryker Competitors

Stryker’s key competitors and comparable public companies in the medical devices sector include Intuitive Surgical, Johnson & Johnson, and Abbott Laboratories. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Stryker stacks up by comparing their revenue breakdown, margins, and growth metrics.

Stryker Competitors

Stryker’s key competitors and comparable public companies in the medical devices sector include Intuitive Surgical, Johnson & Johnson, and Abbott Laboratories. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Stryker stacks up by comparing their revenue breakdown, margins, and growth metrics.

Stryker Competitors

Stryker’s key competitors and comparable public companies in the medical devices sector include Intuitive Surgical, Johnson & Johnson, and Abbott Laboratories. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Stryker stacks up by comparing their revenue breakdown, margins, and growth metrics.

Stryker Competitors

Stryker’s key competitors and comparable public companies in the medical devices sector include Intuitive Surgical, Johnson & Johnson, and Abbott Laboratories. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Stryker stacks up by comparing their revenue breakdown, margins, and growth metrics.

Stryker Competitors

Stryker’s key competitors and comparable public companies in the medical devices sector include Intuitive Surgical, Johnson & Johnson, and Abbott Laboratories. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Stryker stacks up by comparing their revenue breakdown, margins, and growth metrics.

Stryker Competitors

Stryker’s key competitors and comparable public companies in the medical devices sector include Intuitive Surgical, Johnson & Johnson, and Abbott Laboratories. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Stryker stacks up by comparing their revenue breakdown, margins, and growth metrics.

Stryker Competitors

Stryker’s key competitors and comparable public companies in the medical devices sector include Intuitive Surgical, Johnson & Johnson, and Abbott Laboratories. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Stryker stacks up by comparing their revenue breakdown, margins, and growth metrics.

Revenue Breakdown

Segment 2024 2023 YoY Growth
MedSurg & Neurotechnology $14,100 $12,900 +9.3%
Orthopaedics & Spine $8,500 $7,800 +9.0%
Total Revenue $22,600 $20,500 +10.2%

MedSurg & Neurotechnology — 62% of Revenue

Orthopaedics & Spine — 38% of Revenue

Income Statement Overview

Metric 2024 2023
Total Revenue $22,600 $20,500
Cost of Revenue $8,700 $8,100
Gross Profit $13,900 $12,400
Operating Expenses $9,400 $8,600
Operating Income $4,500 $3,800
Net Income $3,500 $3,000

All values in millions USD unless otherwise stated.

Key Financial Metrics

  • Gross Margin: 61.5%
  • Operating Margin: 19.9%
  • Revenue Growth: 10.2%

Is Stryker Profitable?

Yes, Stryker is profitable. The company reported net income of $3,500 on total revenue of $22,600. With an operating margin of 19.9%, Stryker demonstrates solid profitability for the medical devices sector. The gross margin of 61.5% reflects Stryker’s pricing power and cost structure.

What to Watch

  1. Mako robotic platform adoption and procedure volume growth
  2. MedSurg segment growth driven by hospital capital spending recovery
  3. M&A pipeline and integration of recent acquisitions
  4. International market expansion, particularly in emerging markets

Stryker (SYK) Financial Summary

Stryker (SYK) is a medical devices company that generated $22,600 in total revenue in fiscal year 2024. Revenue grew 10.2% year-over-year. The company earned $3,500 in net income, making it profitable. For a deeper look at Stryker’s revenue breakdown, business segments, and financial performance, review the detailed analysis above.

Frequently Asked Questions

How does Stryker make money?

A breakdown of Stryker (SYK) financials. See how Stryker makes money from MedSurg & Neurotechnology, Orthopaedics & Spine using their 2024 annual report.

What is Stryker's stock ticker symbol?

Stryker trades on the stock market under the ticker symbol SYK.

What is Stryker's market cap?

Stryker's market capitalization is approximately $130B.

What sector does Stryker operate in?

Stryker operates in the Medical Devices sector.

Is Stryker publicly traded?

Yes, Stryker is a publicly traded company listed under the ticker SYK with a market capitalization of approximately $130B.